--
--(--)
--
--(--)
Expected P&L on Expiry
Key Stats
0.00DAY`S RANGE0.00
0.00
0.00
--
--
--
--
--
--
--
Pricing Model
--
--
--
--
--
--
About TSHA20260417P4
Biological Technology
Taysha Gene Therapies, Inc. was originally incorporated under Texas law on September 20, 2019. The Company was converted to a Delaware corporation on February 13, 2020. The Company is a patient-centric gene therapy company dedicated to the development and development of commercialized AAV-based gene therapies for the treatment of rare and large patient populations of central nervous system monogenic diseases.
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
